Abstract: Compositions comprising a red blood cell (RBC) having non-toxically coupled thereto a nanoparticle having a low shear modulus or low Young's modulus of less than 10 MPa and containing a drug are provided. In one embodiment, the nanoparticles are optionally coated with protein. In another embodiment, the nanoparticle has no cell-specific targeting moiety or tissue-specific targeting moiety or organ-specific targeting moiety associated therewith. Methods of delivering selected drugs to target organs use these compositions both in vivo and ex vivo treatment of disease and for imaging.
Type:
Grant
Filed:
October 2, 2017
Date of Patent:
September 21, 2021
Assignees:
The Trustees of the University of Pennsylvania, The Regents of the University of California
Inventors:
Vladimir Muzykantov, Jacob Brenner, Jacob Myerson, Daniel Pan, Samir Suresh Mitragotri
Abstract: Described herein are suspensions of helical polycarbodiimide polymers that ‘cloak’ nanotubes, thereby effecting control over nanotube emission, providing a new mechanism of environmental responsivity, and enabling precise control over sub-cellular localization. The helical polycarbodiimide polymers described herein are water soluble, easily modifiable, and have unique architectures that facilitate their application in radiopharmaceutical delivery and imaging methods, in therapeutics and therapeutic delivery methods, and their use as sensors—both in conjunction with carbon nanotubes, and without nanotubes.
Type:
Grant
Filed:
December 31, 2018
Date of Patent:
August 24, 2021
Assignee:
MEMORIAL SLOAN KETTERING CANCER CENTER
Inventors:
Daniel Heller, Januka Budhathoki-Uprety
Abstract: An aqueous disinfecting solution and uses and methods of disinfection and sanitization employing same. The solution comprises at least one inorganic salt selected from the group consisting of sulfate, chloride, bromide, iodide, carbonate, phosphate, fluoride, and nitrate salts in a concentration of from about 0.1 to about 15 wt. %; at least one peroxide compound in a concentration of from about 0.01 to about 8 wt. %; and at least one amphoteric amine oxide surfactant having the formula R1R2R3NO wherein each of R1, R2, and R3 is independently a saturated, unsaturated, substituted or unsubstituted linear or branched alkyl group having from 1 to 28 carbon atoms in a concentration of from about 0.01 to about 15 wt. %.
Type:
Grant
Filed:
February 16, 2018
Date of Patent:
August 3, 2021
Assignee:
Diversey, Inc.
Inventors:
Faraz Alderson, Pierre Grascha, Matthew Alasdair Timothy Slack
Abstract: Particles are provided for use in therapeutic and/or diagnostic procedures. The particles include poly[bis(trifluoroethoxy) phosphazene] and/or a derivatives thereof which may be present throughout the particles or within an outer coating of the particles. The particles can also include a core having a hydrogel formed from an acrylic-based polymer. Barium sulfate may also be provided to the core of the particles as a coating or absorbed within the core of the particles. The particles can be used to minimize blood flow to mammalian tissues by occluding at least a portion of a blood vessel of the mammal, or to deliver an active agent to a localized area within a body of a mammal by contacting a localized area with at least one of the particles. Farther, the particles are useful in sustained release formulations including active agent(s) for oral administration, as tracer particles for injection into the bloodstream of a mammal or for use in enhanced ultrasound imaging.
Abstract: The present invention relates to novel dendrimer conjugates, methods for their preparation and their use for treatment of diseases. The invention discloses a new method for the delivery of dendrimer conjugates with therapeutically active molecules into the cell by utilizing transmembrane solute carrier proteins enabling uptake of the inventive dendrimer conjugates. Particular subject-matter of the present invention is a conjugate of the formula E-[G-L-D(OSO3?M+)n]m, wherein E is a therapeutic or diagnostic effector molecule, wherein D(OSO3?M+)n is a dendrimer D carrying a number n of sulfate groups OSO3?M+, wherein the number n of sulfate groups is selected from 6 to 96, wherein M is a cationic inorganic or organic counter ion to the anionic sulfate group, wherein L is a linker or spacer between D and E, wherein G is a connecting functional group forming the attachment between L and E, and wherein m is an integer from 1 to 20.
Abstract: A method of treatment of viral infection in a subject comprising administering to the subject a copolymer comprising an acrolein derived segment or a polyacrolein oligomer segment and a polyalkylene glycol oligomer segment, the copolymer having a molecular weight of no more than 1500 Daltons.
Type:
Grant
Filed:
February 17, 2017
Date of Patent:
June 29, 2021
Assignee:
RECCE PHARMACEUTICALS LTD
Inventors:
Graham John Hamilton Melrose, Michele Keryn Dilizia
Abstract: Disclosed are methods of antimicrobial treatment using ionic liquids (ILs), IL complexes, polymers comprising ILs, and polymers comprising neutral ethylene diamine compounds. Also disclosed are novel IL complexes, polymers comprising ILs, and polymers comprising neutral ethylene diamine compounds.
Type:
Grant
Filed:
November 20, 2017
Date of Patent:
June 8, 2021
Assignee:
Massachusetts Institute of Technology
Inventors:
T. Alan Hatton, Timothy Kuan-Ta Lu, Paul Brown, Cesar de la Fuente Nunez, Sahag Voskian
Abstract: This invention discloses bioerodible devices, such as implants for delivering therapeutic agents, particularly large molecules such as proteins and antibodies, in a controlled manner. The devices comprise a porous silicon-based carrier material impregnated with the therapeutic agent. The device may be used in vitro or in vivo to deliver the therapeutic agent, preferably in a controlled fashion over an intended period of time such as over multiple days, weeks or months. The device may be used for treating or preventing conditions of a patient such as chronic diseases.
Type:
Grant
Filed:
May 5, 2016
Date of Patent:
June 8, 2021
Assignee:
EYEPOINT PHARMACEUTICAS, INC.
Inventors:
Paul Ashton, Leigh T. Canham, Christian Barnett
Abstract: To provide a polymer having a high tumor/blood ratio. The present invention provides a polymer represented by the following formula (P1): wherein in the formula (P1), R0 represents any of a residue or a functional group derived from a cationic polymerization initiator; L represents a linker and L may not be present; n represents an integer of 1 or more; D represents a dye backbone of a dye having absorption in the near-infrared region.
Abstract: The present disclosure relates to, inter alia, a green technology for crosslinking protein molecules for various uses, where the protein molecules can be contained in protein fibers such as, but not limited to, human hair, animal fibers, and mixtures thereof. In one aspect, the present disclosure relates to a crosslinking agent comprising an oxidized sugar having at least two aldehyde groups. In another aspect, the present disclosure relates to a method of crosslinking protein fibers. This method involves providing the aforementioned crosslinking agent and infiltrating a plurality of non-crosslinked protein fibers with the crosslinking agent under conditions effective to cause protein molecules contained in the non-crosslinked protein fibers to become crosslinked, thereby yielding a population of crosslinked protein fibers.
Abstract: Disclosed herein are embodiments of composites and compositions that can be used for therapeutic applications in vivo and/or in vitro. The disclosed composites can comprise cores having magnetic nanoparticles, quantum dots, or combinations thereof and zwitterionic polymeric coatings that facilitate solubility and bioconjugation. The compositions disclosed herein can comprise the composites and one or more biomolecules, drugs, or combinations thereof. Also disclosed herein are methods of making the composites, composite components, and methods of making quantum dots for use in the composites.
Type:
Grant
Filed:
January 16, 2018
Date of Patent:
May 4, 2021
Assignee:
Board of Regents of the Nevada System of Higher Education, on behalf of the University of Nevada, Reno
Abstract: Couplers for ultrasound probes can have a solid coupler body and a probe attachment member that is secured to a coupler body. The probe attachment member may extend upwardly from the coupler body. The probe attachment member may frictionally and/or adhesively engage with an ultrasound probe, thereby attaching and/or holding the coupler body to an end of the ultrasound probe. The coupler body may include at least one open channel that that extends through the coupler body to define a fluid path. The at least one open channel may be sized to hold and/or contain a fluid and/or gel in and/or on the coupler body and only release the fluid and/or gel when a force is exerted at a top surface of the coupler body. A coupler may be provided in a package in an orientation and easy to use fashion that may aid in attaching the coupler to an end of an ultrasound probe.
Abstract: Various exemplary photoreactions can be provided, including reactions generally based on triplet-triplet annihilation upconversion. Representative photosensitizers include PdPc(OBu)8 and PtTPTNP. Representative annihilators include FDPP and TTBP. Such exemplary photoreactions, systems and methods may be used in a variety of applications, including various biological or physical applications. Exemplary methods can also be provided for making or using such systems, photoreactions, kits including such systems, or the like.
Type:
Grant
Filed:
March 12, 2019
Date of Patent:
April 20, 2021
Assignees:
The Trustees of Columbia University in the City of New York, President and Fellows of Harvard College
Inventors:
Luis M. Campos, Daniel N. Congreve, Andrew Brian Pun, Kealan Fallon, Emily Marie Churchill, Tomislav Rovis, Benjamin Ravetz
Abstract: A synthetic calcium phosphate-based biomedical material comprising gadolinium. The material may comprises a compound having the general chemical formula: Ca10?yGdy(PO4)6?x(SiO4)x(OH)2?x+y where 0<x<1.3 and 0<y<1.3.
Type:
Grant
Filed:
January 8, 2020
Date of Patent:
April 6, 2021
Assignees:
UNIVERSITY COURT OF THE UNVERSITY OF ABERDEEN, APATECH LIMITED
Inventors:
Iain Ronald Gibson, Janet Mabel Scott Skakle, Nigel Smith, Thomas Buckland
Abstract: A phosphor-containing drug activator activatable from a Monte Carlo derived x-ray exposure for treatment of a diseased site. The activator includes an admixture or suspension of one or more phosphors capable of emitting ultraviolet and visible light upon interaction with x-rays, wherein a distribution of the phosphors in the diseased target site is based on a Monte Carlo derived x-ray dose. A system for treating a disease in a subject in need thereof, includes the drug activator and a photoactivatable drug, one or more devices which infuse the photoactivatable drug and the activator including the pharmaceutically acceptable carrier into a diseased site in the subject; and an x-ray source which is controlled to deliver the Monte Carlo derived x-ray exposure to the subject for production of ultraviolet and visible light inside the subject to activate the photoactivatable drug.
Type:
Grant
Filed:
November 21, 2017
Date of Patent:
March 9, 2021
Assignees:
IMMUNOLIGHT, LLC, DUKE UNIVERSITY
Inventors:
Mark Oldham, Justus Adamson, Paul Yoon, Harold Walder, Frederic A. Bourke, Jr., Zakaryae Fathi, Wayne F. Beyer
Abstract: The invention provides polymers having the structure: wherein Q, Q?, E, R1, a, b, c, d, and n are described herein. The invention further provides compositions comprising the polymers such as, personal care, hair care, coatings, and battery compositions. The invention furthermore provides hair care compositions comprising the polymers described herein.
Type:
Grant
Filed:
August 4, 2016
Date of Patent:
February 23, 2021
Assignee:
ISP INVESTMENTS LLC
Inventors:
Osama M. Musa, Ezat Khosravi, Peter Andrew King
Abstract: A composition comprising poly(amidoamine) (PAMAM) hydroxyl-terminated dendrimers covalently linked to at least one therapeutic, prophylactic or diagnostic agent for the treatment or alleviation of one or more symptoms of a brain tumor have been developed. The dendrimers comprise one or more ethylene diamine-core poly(amidoamine) (PAMAM) hydroxyl-terminated generation-4, 5, 6, 7, 8, 9, or 10, most preferably generation 6 (G4-10-OH) dendrimers. The G6 dendrimers have demonstrated unexpectedly high uptake into the brain. The dendrimers provide a means for selective delivery through the blood brain barrier (“BBB”) of chemotherapeutic, immunotherapeutic and palliative agents. The dendrimers also have the advantage that two different classes of compounds, having one or more mechanisms of action can be bound to the dendrimers, providing simultaneous delivery. The dendrimers may be administered alone by intravenous injection, or as part of a multi-prong therapy with radiation.
Type:
Grant
Filed:
August 13, 2015
Date of Patent:
February 16, 2021
Assignee:
THE JOHNS HOPKINS UNIVERSITY
Inventors:
Kannan Rangaramanujam, Betty M. Tyler, Fan Zhang, Panagiotis Mastorakos, Manoj K. Mishra, Antonella Mangraviti
Abstract: The present invention concerns a system for preparing a ready-to-use peritoneal dialysis fluid. The system comprises a) a proportioning device; b) at least one source of water; c) at least one source of first concentrate adapted for connection with a) and b), d) at least one source of second concentrate adapted for connection with a) and b), and optionally, e) at least one source of further concentrate adapted for connection with a) and b), wherein the first concentrate comprises glucose and has a pH of between 1.5 and 4, and wherein the second concentrate comprises a physiologically acceptable buffer and has a pH of between 5.5 and 9.0.
Type:
Grant
Filed:
May 5, 2017
Date of Patent:
January 19, 2021
Assignee:
Gambro Lundia AB
Inventors:
Anders Wieslander, Olof Jansson, Ola Carlsson, Sture Hobro, Karin Sandin, Simon Enarsson
Abstract: There are described magnetic nanoparticles the surface of which is functionalized with catechol and constructs comprising a plurality of said nanoparticles encapsulated in a biocompatible polymer matrix, wherein a molecule with therapeutic action is optionally dispersed, said polymer matrix optionally being in turn further functionalized; there are further described cells of the immune system incorporating said polymeric constructs giving rise to their engineering.
Type:
Grant
Filed:
January 7, 2015
Date of Patent:
January 12, 2021
Assignee:
COLOROBBIA ITALIA S.P.A.
Inventors:
Giovanni Baldi, Costanza Ravagli, Mauro Comes Franchini, Mario Milco D'Elios, Marisa Benagiano, Marco Bitossi